An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Advanced and recurrent gynecological cancers are associated with poor prognosis and lack
of effective treatment. The developments of the molecular mechanisms on cancer …

Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …

Background This phase II, open-label study evaluated the efficacy and safety of erlotinib as
second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases …

Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …

Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …

Background The aim of this study was to assess the role of skin rash in predicting the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …

Background In a significant percentage of advanced non-small-cell lung cancer (NSCLC)
patients, tumor tissue is unavailable or insufficient for genetic analyses. We prospectively …

Background The therapeutic value of targeted therapies in patients with lung cancer is
reduced when tumours acquire secondary resistance after an initial period of successful …